News
European Commission approves conditionally Jemperli for use in women with mismatch repair-deficient (dMMR)/microsatellite instability-high recurrent or advanced endometrial cancer. GSK
GlaxoSmithKline has announced the European Commission has granted conditional marketing authorisation for Jemperli(dostarlimab), a programmed death receptor-1 (PD-1)-blocking antibody, for use in women with mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer who have progressed on or following prior treatment with a platinum containing regimen.
The approval makes dostarlimab the first anti-PD-1 therapy available for endometrial cancer in Europe.
Condition: Mismatch Repair Deficient Endometrial Cancer
Type: drug